Antimicrobial resistance: one world, one fight!

Antimicrobial Resistance and Infection Control

Didier Pittet⁴  Alex Van Belkum¹  Mirko Saam⁷  Ramanan Laxminarayan⁵  Jan Kluytmans³  Vincent Jarlier⁶  Herman Goossens²  Hanan H. Balkhy⁸  Stephan Harbarth⁴ 

[1]BioMérieux, Microbiology R&D Department, La Balme Les Grottes, France

[2]Department of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium

[3]University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands

[4]Infection Control Programme and WHO Collaborating Centre on Patient Safety, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland

[5]Center for Disease Dynamics, Economics & Policy (CDDEP), Washington, DC, USA

[6]Laboratory of Bacteriology-Hygiene, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France

[7]Communication in Science, Rue des Maraîchers 8, Geneva, Switzerland

[8]King Saud bin Abdulaziz University for Health Sciences, College of Medicine, Riyadh, Saudi Arabia

关键词: World healthcare-associated infections resistance forum;    Global health;    Animal health;    Surveillance networks;    Hand hygiene;    Infection control;    One health;    Antibiotic stewardship;    Antimicrobial conservation;    Antimicrobial resistance;   

Others  :  1234943
DOI  :  10.1186/s13756-015-0091-2

 received in 2015-10-29, accepted in 2015-11-08,  发布年份 2015

【 摘 要 】

The lack of new antibiotic classes calls for a cautious use of existing agents. Yet, every 10 min, almost two tons of antibiotics are used around the world, all too often without any prescription or control. The use, overuse and misuse of antibiotics select for resistance in numerous species of bacteria which then renders antimicrobial treatment ineffective. Almost all countries face increased antimicrobial resistance (AMR), not only in humans but also in livestock and along the food chain. The spread of AMR is fueled by growing human and animal populations, uncontrolled contamination of fresh water supplies, and increases in international travel, migration and trade. In this context of global concern, 68 international experts attending the fifth edition of the World HAI Resistance Forum in June 2015 shared their successes and failures in the global fight against AMR. They underlined the need for a “One Health” approach requiring research, surveillance, and interventions across human, veterinary, agricultural and environmental sectors. This strategy involves concerted actions on several fronts. Improved education and increased public awareness are a well-understood priority. Surveillance systems monitoring infections need to be expanded to include antimicrobial use, as well as the emergence and spread of AMR within clinical and environmental samples. Adherence to practices to prevent and control the spread of infections is mandatory to reduce the requirement of antimicrobials in general care and agriculture. Antibiotics need to be banned as growth promoters for farm animals in countries where it has not yet been done. Antimicrobial stewardship programmes in animal husbandry have proved to be efficient for minimising AMR, without compromising productivity. Regarding the use of antibiotics in humans, new tools to provide highly specific diagnoses of pathogens can decrease diagnostic uncertainty and improve clinical management. Finally, infection prevention and control measures – some of them as simple as hand hygiene – are essential and should be extended beyond healthcare settings. Aside from regulatory actions, all people can assist in AMR reduction by limiting antibiotic use for minor illnesses. Together, we can all work to reduce the burden of AMR.

【 授权许可】

   
2015 Harbarth et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis. 15 October 2015. OnlineFirst. doi:10.1016/S1473-3099(15)00270-4.
• [2]Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA et al.. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014; 14:742-50.
• [3]Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature. 2011; 476:393-4.
• [4]Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011; 11(9):692-701.
• [5]Centers for Disease Control and Prevention. Antimicrobial Resistance Threat Report. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 21 Oct 2015.
• [6]European Commission. Action plan against the rising threats from Antimicrobial Resistance. Communication from the Commission to the European Parliament and the Council. COM (2011) 748. http://ec.europa.eu/dgs/health_food-safety/docs/communication_amr_2011_748_en.pdf. Accessed 21 Oct 2015.
• [7]Office for National Statistics. Deaths Involving MRSA: England and Wales, 2008 to 2012. Statistical Bulletin. August 2013. http://www.ons.gov.uk/ons/rel/subnational-health2/deaths-involving-mrsa/2008-to-2012/stb---mrsa.html. Accessed 21 Oct 2015.
• [8]Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I et al.. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011; 11(1):30-38.
• [9]Gonçalves Pereira S, Cristina Rosa A, Cardoso O. Virulence factors as predictive tools for drug resistance in Pseudomonas aeruginosa. Virulence. 2015; 6(7):1-5.
• [10]Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature. 2014; 509:555-7.
• [11]World Economic Forum. Global Risks Report 2013 - Eigth edition. http://www.weforum.org/reports/global-risks-2013-eighth-edition. Accessed 21 Oct 2015.
• [12]Science Ministers of the G8. G8 Science Ministers Statement. London, UK. 2013. https://www.gov.uk/government/publications/g8-science-ministers-statement-london-12-june-2013. Accessed 21 Oct 2015.
• [13]WHO. Antimicrobial resistance: global report on surveillance. April 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 21 Oct 2015.
• [14]The Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance, chaired by Jim O’Neill. December 2014. http://amr-review.org/Publications. Accessed 21 Oct 2015.
• [15]The White House Press Office. President’s 2016 Budget Proposes Historic Investment to Combat Antibiotic-Resistant Bacteria to Protect Public Health. Press release on January 27, 2015. http://www. whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a webcite
• [16]G7 Leaders’ Declaration Think Ahead. Act Together. 7–8 June 2015. https://www.g7germany.de/Content/DE/_Anlagen/G8_G20/2015-06-08-g7-abschluss-eng.pdf?__blob=publicationFile&v=5. Accessed 21 Oct 2015.
• [17]Editorial: The G7 and global health: inaction or incisive leadership? The Lancet. 2015;385:2433. doi:10.1016/S0140-6736(15)61121-7.
• [18]WHO. Worldwide country situation analysis: response to antimicrobial resistance. April 2015. http://www.who.int/drugresistance/documents/situationanalysis/en/. Accessed 21 Oct 2015.
• [19]WHO. Draft global action plan for antimicrobial resistance. May 2015. http://www.who.int/drugresistance/global_action_plan/en/. Accessed 21 Oct 2015.
• [20]Huttner B, Goossens H, Verheij T, Harbarth S. CHAMP consortium. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis. 2010; 10:17-31.
• [21]Goossens H. European strategies to control antibiotic resistance and use. Ann Clin Microbiol. 2014; 17(1):1-8.
• [22]WHO. Bulletin of the World Health Organization, Volume 89, Number 1, January 2011, 1–80. http://www.who.int/bulletin/volumes/89/1/en/. Accessed 21 Oct 2015.
• [23]Bernier A, Delarocque-Astagneaua E, Ligiera C, Vibeta MA, Guillemota D, Watiera L. Outpatient antibiotic Use in France between 2000 and 2010: after the nationwide campaign, It is time to focus on the elderly. Antimicrob Agents Chemother. 2014; 58(1):71-7.
• [24]Chahwakilian P, Huttner B, Schlemmer B, Harbarth S. Impact of the French campaign to reduce inappropriate ambulatory antibiotic use on the prescription and consultation rates for respiratory tract infections. J Antimicrob Chemother. 2011; 66(12):2872-9.
• [25]Filippini M, Ortiz LG, Masiero G. Assessing the impact of national antibiotic campaigns in Europe. Eur J Health Econ. 2013; 14(4):587-99.
• [26]European Commission. Special Eurobarometer 407 on Antimicrobial Resistance. November 2013. http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_407_en.pdf. Accessed 21 Oct 2015.
• [27]Bruyndonckx R, Hens N, Aerts M, Goossens H, Molenberghs G, Coenen S. Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages. J Antimicrob Chemother. 2014; 69(7):1981-1986.
• [28]LOcal Campaign on Antibiotics ALliance (LOCAAL) study group. Doctors and local media: a synergy for public health information? A controlled trial to evaluate the effects of a multifaceted campaign on antibiotic prescribing (protocol). BMC Public Health. 2011;11:816. doi:10.1186/1471-2458-11-816.
• [29]Dyar OJ, Pulcini C, Howard P, Nathwani D. European medical students: a first multicentre study of knowledge, attitudes and perceptions of antibiotic prescribing and antibiotic resistance. J Antimicrob Chemother. 2014; 69:842-6.
• [30]Thomas G. Tackling antibiotic resistance in veterinary practice: a team approach. Vet. Nurs. 2015; 6(5):298-301.
• [31]Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet. 2013;382(9899):1175–82. doi:10.1016/S0140-6736(13)60994-0.
• [32]Zowawi HM, Abedalthagafi M, Charles FA, Hasanain RH, Harris-Brown T, Kutbi AH, et al. The potential role of social media platforms in community awareness of antibiotic use in the Gulf Cooperation Council States. Luxury or necessity? J Med Internet Res (in press).
• [33]Rocha-Pereira N, Lafferty N, Nathwani D. Educating healthcare professionals in antimicrobial stewardship: can online-learning solutions help? J Antimicrob Chemother. Advance Access published October 1, 2015. doi:10.1093/jac/dkv336.
• [34]Laxminarayan R, Duse A, Wattal C, Zaidi A, Wertheim H, Sumpradit N et al.. Antibiotic resistance - the need for global solutions. Lancet Infect Dis. 2013; 13:1057-98.
• [35]Van Boeckel TP, Brower C, Gilbert M, Grenfella BT, Levina SA, Robinsoni TP et al.. Global trends in antimicrobial use in food animals. PNAS. 2015; 112(18):5649-5654.
• [36]Irungu P. Surveillance of antimicrobial resistance from food animals and farmers’ use of antibiotics in livestock production in Kenya. Paper presented at the 2012 annual meeting of the american society of tropical medicine and hygiene in Atlanta. Georgia, USA; 2012. November, 2012
• [37]Gilbert N. Antibiotic resistance marching across Europe. Nature News. Nov 22, 2011. doi:10.1038/nature.2011.9413
• [38]Garcia-Migura L, Hendriksen RS, Fraile L, Aarestrup FM. Antimicrobial resistance of zoonotic and commensal bacteria in Europe: the missing link between consumption and resistance in veterinary medicine. Vet Microbiol. 2014; 170:1-9.
• [39]The Pew Charitable Trusts. Gaps in FDA's Antibiotics Policy. Issue Brief. November 30, 2014. http://www. pewtrusts.org/en/research-and-analysis/issue-briefs/2014/11/gaps-in-fdas-antibiotics-policy webcite
• [40]Teillant A, Laxminarayan R. Economics of Antibiotic Use in U.S. Swine and Poultry Production. Choices Magazine. 1st Quarter 2015. http://www.choicesmagazine.org/choices-magazine/theme-articles/theme-overview/economics-of-antibiotic-use-in-us-swine-and-poultry-production. Accessed 21 Oct 2015.
• [41]http://www.global-pps.com
• [42]Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone resistance in Australia through successful regulation. Emerg Infect Dis. 2012; 18(9):1453-1460.
• [43]Magill SS, Edwards JR, Beldavs ZG, Dumyati G, Janelle SJ, Kainer MA et al.. Prevalence of antimicrobial Use in US acute care hospitals, May-september 2011. JAMA. 2014; 312(14):1438-1446.
• [44]Zowawi HM, Sartor AL, Balkhy HH, Walsh TR, Al Johani SM, AlJindan RY et al.. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers. Antimicrob Agents Chemother. 2014; 58(6):3085-90.
• [45]Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 2013; 26(3):361-80.
• [46]Aly M, Tayeb HT, Al Johani SM, Alyamani EJ, Aldughaishem F, Alabdulkarim I et al.. Genetic diversity of OXA-51-like genes among multidrug-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur J Clin Microbiol Infect Dis. 2014; 33(7):1223-8.
• [47]Combescure C, Graafmans W, Attar H, Donaldson L, Pittet D, Nejad S et al.. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011; 377:228-241.
• [48]European Centre for Disease Prevention and Control. Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm. 2015. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf. Accessed 21 Oct 2015.
• [49]Sharland M, Saroey P, Berezin EN. The global threat of antimicrobial resistance - the need for standardized surveillance tools to define burden and develop interventions. J Pediatr. 2015; 91:410-2.
• [50]Aly M, Balkhy HH. The prevalence of antimicrobial resistance in clinical isolates from gulf corporation council countries. Antimicrob Resist Infect Control. 2012; 19(1):26. BioMed Central Full Text
• [51]Pagani L, Landelle C, Harbarth S. Is patient isolation the single most important measure to prevent the spread of multidrug-resistant microorganisms? Virulence. 2013; 4(2):1-9.
• [52]Mushtaq A, Carvalho M, Jehan F, Chishti N, Khatoon S, Farooqi M et al.. Prevalence, socio-demographic and hygiene profile of patients with blaNDM in a tertiary-care hospital in urban Pakistan. Poster 1068. Copenhagen, Denmark; 2015.
• [53]Mittal G. Abstract-OC 17. Twelth congress of the hospital infection society India (HISICON). Vardhaman Mahavir Medical College & Safdarjung Hospital, Delhi; 2013. February
• [54]Mandal J, Acharya NS, Buddhapriya D, Parija SC. Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant Escherichia coli. Indian J Med Res. 2012; 136:842-849.
• [55]House of Parliament. Office of Science & Technology. Antibiotic Resistance in the Environment. Post Note Number 446, October 2013. http://www.parliament.uk/business/publications/research/briefing-papers/POST-PN-446/antibiotic-resistance-in-the-environment. Accessed 21 Oct 2015.
• [56]Devarajan N, Laffite A, Graham N, Meijer M, Prabakar K, Mubedi JI, et al. Accumulation of Clinically Relevant Antibiotic-Resistance Genes, Bacterial Load, and Metals in Freshwater Lake Sediments in Central Europe. Environ. Sci. Technol. 2015;49(11):6528–37. doi:10.1021/acs.est.5b01031.
• [57]Bréchet C, Plantin J, Sauget M, Thouverez M, Talon D, Cholley P et al.. Wastewater treatment plants release large amounts of extended-spectrum β-lactamase-producing Escherichia coli into the environment. Clin Infect Dis. 2014; 58(12):1658-65.
• [58]Tanner WD, VanDerslice JA, Toor D, Benson LC, Porucznik CA, Goel RK et al.. Development and field evaluation of a method for detecting carbapenem-resistant bacteria in drinking water. Syst Appl Microbiol. 2015; 38(5):351-357.
• [59]WHO. Tackling antibiotic resistance from a food safety perspective in Europe. 2011. http://www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2011/tackling-antibiotic-resistance-from-a-food-safety-perspective-in-europe. Accessed 21 Oct 2015.
• [60]ECDC (European Centre for Disease Prevention and Control), EFSA (European Food Safety Authority) and EMA (European Medicines Agency), 2015. ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA Journal 2015;13(1):4006, 114 pp. doi:10.2903/j.efsa.2015.4006
• [61]Stewardson A, Renzi G, Vaudaux C, Maury N, Brossier C, Fritsch E et al.. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital food: a risk assessment. Infect Control Hosp Epidemiol. 2014; 35:375-383.
• [62]Johnson JR. Personal communication. 2015.
• [63]Price LB, Stegger M, Hasman H, Aziz M, Larsen J, Andersen PS et al.. Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. MBio. 2012; 3(1):e00305-11.
• [64]Madec J-Y, Haenni M, Métayer V, Saras E, Nicolas-Chanoine M-H. High prevalence of the animal-associated blaCTX-M-1 IncI1/ST3 plasmid in human Escherichia coli isolates. Antimicrob Agents Chemother. 2015; 59(9):5860-1.
• [65]Guerra B, Fischer J, Helmuth R. An emerging public health problem: acquired carbapenemase-producing microorganisms are present in food-producing animals, their environment, companion animals and wild birds. Vet Microbiol. 2014; 171(3–4):290-7.
• [66]Zurek L, Ghosh A. Insects represent a link between food animal farms and the urban environment for antibiotic resistance traits. Appl Environ Microbiol. 2014; 80(12):3562-7.
• [67]You Y, Silbergeld EK. Learning from agriculture: understanding low-dose antimicrobials as drivers of resistome expansion. Front Microbiol. 2014; 5:284.
• [68]Pittet D, Donaldson L. Clean care is safer care: a worldwide priority. Lancet. 2005; 8:1246-7.
• [69]Allegranzi B, Gayet-Ageron A, Damani N, Bengaly L, McLaws M-L, Moro M-L et al.. Global implementation of WHO’s multimodal strategy for improvement of hand hygiene: a quasi-experimental study. Lancet Infect Dis. 2013; 13(10):843-51.
• [70]Crouzet T. Clean hands save lives. Editions Age d’Homme, Paris; 2014.
• [71]Grayson ML, Jarvie LJ, Martin R, Johnson PDR, Jodoin ME, McMullan C et al.. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust. 2008; 188(11):633-640.
• [72]Marchaim D, Chopraa T, Pereza F, Hayakawaa K, Lephart PR, Bheemreddya S. Outcomes and genetic relatedness of carbapenem-resistant Enterobacteriaceae at Detroit medical center. Infect. Control Hosp. Epidemiol. 2011; 32(9):861-871.
• [73]Longtin Y, Troillet N, Touveneau S, Boillat N, Rimensberger P, Dharan S et al.. Pseudomonas aeruginosa outbreak in a pediatric intensive care unit linked to a humanitarian organisation residential centre. Ped Infect Dis J. 2010; 29:233-237.
• [74]Chmielarczyk A, Higgins PG, Wojkowska-Mach J, Synowiec E, Zander E, Romaniszyn D et al.. Control of an outbreak of acinetobacter baumannii infections using vaporized hydrogen peroxide. J Hosp Infect. 2012; 81(4):239-245.
• [75]Fournier S, Monteil C, Lepainteur M, Richard C, Brun-Buisson C, Jarlier V. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro Surveill. 2014; 19(19):pii=20802.
• [76]Laxminarayan R, Van Boeckel TP. The value of tracking antibiotic consumption. Lancet Infect Dis. 2014; 14(5):360-361.
• [77]Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE, Gaynes RP. Intensive care antimicrobial resistance epidemiology (ICARE) project and national nosocomial infection surveillance system (NNIS) hospitals. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis. 2002; 8:702-707.
• [78]Hsueh PR, Shyr JM, Wu JJ. Decreased erythromycin use after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan. Clin Infect Dis. 2005; 40:903-905.
• [79]S Levy. Reduced antibiotic use in livestock: how Denmark tackled resistance. Environ Health Perspect. 2014;122:160–165. doi:10.1289/ehp.122-A160.
• [80]Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A et al.. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013; 4:CD003543.
• [81]Granowitz EV, Brown RB. Antibiotic adverse reactions and drug interactions. Crit Care Clin. 2008; 24:421-442.
• [82]National Center for Emerging and Zoonotic Infectious Diseases. Making Health Care Safer. Vital Signs. 2015. http://www.cdc.gov/vitalsigns/stop-spread/index.html. Accessed 21 Oct 2015.
• [83]Harbarth S. Should the development of new antibiotics be a public health priority? Curr Opin Crit Care. 2007; 13:554-556.
• [84]Laxminarayan R. Antibiotic effectiveness: balancing conservation against innovation. Science. 2014; 345(6202):1299-301.
• [85]Selçuklu A, Demiraslan H, Tucer B, Cevahir F, Alp E, Aysegul Ulu-Kilic A et al.. Economic evaluation of appropriate duration of antibiotic prophylaxis for prevention of neurosurgical infections in a middle-income country. Am J Infect Control. 2015; 43(1):44-47.
• [86]Huttner B, Harbarth S, Nathwani D, on behalf of the ESCMID Study Group for Antibiotic Policies (ESGAP). Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect. 2014;20:954–62.
• [87]Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P. Improving antibiotic Use among hospitalized patients. (MMWR). 2014; 3(09):194-200.
• [88]Agerso Y, Aarestrup F. Voluntary ban on cephalosporin use in danish pig production has effectively reduced extended-spectrum cephalosporinase-producing Escherichia coli in slaughter pigs. J Antimicrob Chemother. 2013; 68(3):569-572.
• [89]Wielinga PR. Evidence-based policy for controlling antimicrobial resistance in the food chain in Denmark. Food Control. 2014; 40:185-192.
• [90]Collignon P. Personal communication. 2015.
• [91]Dutil L, Irwin R, Finley R, Ng LK, Avery B, Boerlin P et al.. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis. 2010; 16(1):48-54.
• [92]Central Veterinary Institute (Wageningen University), Food and Consumer Product Safety Authority, National Institute for Public Health and the Environment. MARAN-2013: Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2012. http://www.wageningenur.nl/upload_mm/7/8/9/52388c6c-858c-483c-b57d-227029fe778a_005738_Nethmap_2013%20def_web.pdf Accessed 21 Oct 2015.
• [93]Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward. Phil Trans R Soc B. 2015; 370:20140085.
• [94]Food and Agriculture Organization of the United Nations and World Health Organization. Codex texts on foodborne antimicrobial resistance. Rome, Italy. 2015. ISBN 978-92-5-008610-1
• [95]Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections. Emerg Infect Dis. 2014; 20(7):1170-1175.
• [96]Ghafur A, Devarajan V. Monotherapy versus combination therapy against XDR gram negatives: an unresolved conundrum, poster No.2291. ICAAC, San Diego; 2015.
• [97]Zimmerman MS, Assous MV, Bdolah-Abram T, Lachish T, Yinnon AM, Wiener-Well Y. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control. 2013; 41:190-4.
• [98]Kazi M, Nikam C, Shetty A, Rodrigues C. Dual-tubed multiplex-PCR for molecular characterization of carbapenemases isolated among Acinetobacter spp. and Pseudomonas spp. JAM. 2015; 118(5):1096-1102.
• [99]Bettiol E, Harbarth S. Development of new antibiotics: taking off finally? Swiss Med Wkly. 2015; 145:w14167.
• [100]Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al.. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing: importance of combination therapy. Clin Infect Dis. 2012; 55:943-950.
• [101]Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014; 20:862-872.
• [102]Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U. Combination therapy for carbapenem-resistant gram-negative bacteria. J Antimicrob Chemoter. 2014; 69(9):2305-2309.
• [103]Ghafur A, Kannaian P, Tayade A. Clinical Study On Carbapenem Sensitive & Carbapenem Resistant Bacteremia In Neutropenic & Non-Neutropenic Patients - The First Series From India. P1368. ECCMID. Berlin, Germany. April 2013.
• [104]Ghafur A, Vidyalakshmi PR, Murali A, Priyadarshini K, Thirunarayan MA. Emergence of Pan-drug resistance amongst gram negative bacteria! the first case series from India. J of Microbiol. Infect. Dis. 2014; 4(3):86-91.
• [105]Gaurav G, Lalawmpuia H, Maitrayee S, Sanjay B, Mammen C. Colistin-resistant Klebsiella pneumoniae: report of a cluster of 24 cases from a new oncology center in eastern India. Infect Control Hosp Epidemiol. 2014; 35(8):1076-1077.
• [106]Harbarth S, Hackett J, Theuretzbacher U. Antibiotic research and development: business as usual? J Antimicrob Chemother. 2015; 70:1604-7.
• [107]Nordmann P, Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2013; 68:487-489.
• [108]Chmelnitsky I, Shklyar M, Leavitt A, Sadovsky E, Navon-Venezia S, Ben Dalak M et al.. Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. Diagn Microbiol Infect Dis. 2014; 79(2):255-260.
• [109]Grundmann H. Personal communication. 2015.
• [110]Jarlier V, Carlet J, McGowan J, Goossens H, Voss A, Harbarth S et al.. Priority actions to fight antibiotic resistance: results of an international meeting. Antimicrob Resis Infect Contr. 2012; 1(1):17. BioMed Central Full Text
• [111]Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A et al.. Antimicrobial resistance: a global view from the 2013 world healthcare-associated infections forum. Antimicrob Resis Infect Contr. 2013; 2(1):31. BioMed Central Full Text
• [112]Berglund B. Environmental dissemination of antibiotic resistance genes and correlation to anthropogenic contamination with antibiotics. Inf Ecol Epidemiol. 2015; 5:28564.
• [113]Klein M, Kimmelman LJ. The role of spontaneous variants in the acquisition of streptomycin resistance by the shigellae. J Bacteriol. 1946; 52:471-479.
• [114]Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Antimicrob Agents Chemother. 2015; 59(4):1922-1930.